Cargando…

Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field

Mutations of Nucleophosmin (NPM1) are the most common genetic abnormalities in adult acute myeloid leukaemia (AML), accounting for about 30% of cases. NPM1-mutated AML has been recognized as distinct entity in the 2017 World Health Organization (WHO) classification of lympho-haematopoietic neoplasms...

Descripción completa

Detalles Bibliográficos
Autores principales:	Falini, Brunangelo, Sciabolacci, Sofia, Falini, Lorenza, Brunetti, Lorenzo, Martelli, Maria Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056374/ https://www.ncbi.nlm.nih.gov/pubmed/33879827 http://dx.doi.org/10.1038/s41375-021-01222-4

Ejemplares similares

Current status and future perspectives in targeted therapy of NPM1-mutated AML
por: Ranieri, Roberta, et al.
Publicado: (2022)

The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein
por: Pianigiani, Giulia, et al.
Publicado: (2022)

CD123 Is Consistently Expressed on NPM1-Mutated AML Cells
por: Perriello, Vincenzo Maria, et al.
Publicado: (2021)

PB1762: A NEW MONOCLONAL ANTIBODY PROVIDES INSIGHTS ON NPM1 MUTANT SUBCELLULAR EXPRESSION, INTRACLONAL CELL DIFFERENTIATION AND MRD IN NPM1-MUTATED AML
por: Falini, Brunangelo, et al.
Publicado: (2023)

IDH1-R132 changes vary according to NPM1 and other mutations status in AML
por: Falini, Brunangelo, et al.
Publicado: (2019)

A Curious Novel Combination of Nucleophosmin (NPM1) Gene Mutations Leading to Aberrant Cytoplasmic Dislocation of NPM1 in Acute Myeloid Leukemia (AML)
por: Venanzi, Alessandra, et al.
Publicado: (2021)

Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML
por: Pianigiani, Giulia, et al.
Publicado: (2022)

GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations
por: Sportoletti, Paolo, et al.
Publicado: (2019)

Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML
por: Gionfriddo, Ilaria, et al.
Publicado: (2021)

Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML
por: Martelli, Maria Paola, et al.
Publicado: (2021)

All‐trans retinoic acid (ATRA) in non‐promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low‐dose Ara‐C in three elderly patients with NPM1‐mutated AML unfit for intensive chemotherapy and review of the literature
por: Forghieri, Fabio, et al.
Publicado: (2016)

Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy
por: Wu, Hsin-Chieh, et al.
Publicado: (2021)

Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia
por: Forghieri, Fabio, et al.
Publicado: (2019)

Generation of the first monoclonal antibody using mouse hybridomas
por: Falini, Brunangelo
Publicado: (2022)

Significance of NPM1 Gene Mutations in AML
por: Hindley, Andrew, et al.
Publicado: (2021)

The antagonistic duality of NPM1 mutations in AML
por: Khan, Irum, et al.
Publicado: (2022)

NPM 1 Mutations in AML—The Landscape in 2023
por: Sharma, Naman, et al.
Publicado: (2023)

Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients
por: De Clara, Etienne, et al.
Publicado: (2017)

Bone Marrow Clonogenic Myeloid Progenitors from NPM1-Mutated AML Patients Do Not Harbor the NPM1 Mutation: Implication for the Cell-Of-Origin of NPM1+ AML
por: Diaz de la Guardia, Rafael, et al.
Publicado: (2020)

NPM1 Deletion Is Associated with Gross Chromosomal Rearrangements in Leukemia
por: La Starza, Roberta, et al.
Publicado: (2010)

Biological and therapeutic implications of a unique subtype of NPM1 mutated AML
por: Mer, Arvind Singh, et al.
Publicado: (2021)

ARPIR: automatic RNA-Seq pipelines with interactive report
por: Spinozzi, Giulio, et al.
Publicado: (2020)

Targeted therapy in NPM1-mutated AML: Knowns and unknowns
por: Wang, Rong, et al.
Publicado: (2022)

The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML
por: von Palffy, Sofia, et al.
Publicado: (2022)

Hematopoietic differentiation at single-cell resolution in NPM1-mutated AML
por: Duchmann, Matthieu, et al.
Publicado: (2022)

Recent advances in understanding and managing hairy cell leukemia
por: Roider, Tobias, et al.
Publicado: (2018)

A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas
por: Falini, Brunangelo, et al.
Publicado: (2022)

Switch of the mutation type of the NPM1 gene in acute myeloid leukemia (AML): relapse or secondary AML?
por: Webersinke, G, et al.
Publicado: (2014)

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
por: Fiskus, Warren, et al.
Publicado: (2022)

Germline NPM1 mutations lead to altered rRNA 2’-O-methylation and cause dyskeratosis congenita
por: Nachmani, Daphna, et al.
Publicado: (2019)

The NPM1 Mutation Type Has No Impact on Survival in Cytogenetically Normal AML
por: Pastore, Friederike, et al.
Publicado: (2014)

Spontaneous remission in three cases of AML M5 with NPM1 mutation
por: Camus, Vincent, et al.
Publicado: (2015)

NPM1 Mutational Status Underlines Different Biological Features in Pediatric AML
por: Tregnago, Claudia, et al.
Publicado: (2021)

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
por: Issa, Ghayas C., et al.
Publicado: (2022)

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1
por: Mill, Christopher P., et al.
Publicado: (2023)

Polatuzumab‐bendamustine‐rituximab as bridge to CD19‐directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax
por: Perriello, Vincenzo Maria, et al.
Publicado: (2023)

Genomics of Hairy Cell Leukemia
por: Tiacci, Enrico, et al.
Publicado: (2017)

An intensive approach to treatment for older patients with relapsed isolated NPM1 mutated AML
por: Dukka, Srivasavi, et al.
Publicado: (2015)

Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration
por: Cappelli, Luca Vincenzo, et al.
Publicado: (2021)

S130: NPM1 MUTATED AML: IMPACT OF CO-MUTATIONAL PATTERNS - RESULTS OF THE EUROPEAN HARMONY ALLIANCE
por: Hernández-Sánchez, A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tv1ks1l6vh0gnd6ndm749a7rpi